A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

NCT03740373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
DRUG: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold

Sponsor

AstraZeneca